Orexo and SVF Vaccines partner on mRNA vaccine formulation research
What happened
Orexo AB and SVF Vaccines AB announced a research collaboration to investigate Orexo’s proprietary AmorphOX® powder-based drug delivery technology. The project aims to determine if this technology can create stable powder-based formulations of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines. The collaboration combines Orexo’s expertise in powder formulation with SVF Vaccines’ vaccine development knowledge.
From news-medical.net
Why it matters
The collaboration addresses formulation challenges related to maintaining the stability of mRNA and its lipid carrier, which often complicate storage and distribution. If successful, the initial program could support further work toward intranasal administration of these vaccines.
From news-medical.net
Who's involved
- OrexoSwedish pharmaceutical company partnering with SVF Vaccines on vaccine formulation research.
- Nikolaj SørensenPresident and CEO of Orexo AB.
- Matti SällbergChief Scientific Officer of SVF Vaccines.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- OrexoSpeculative
The collaboration might validate Orexo's core AmorphOX® technology in the high-value mRNA vaccine market, potentially increasing revenue.
- Matti SällbergSpeculative
The strategic partnership could enhance SVF Vaccines' R&D capabilities to solve core vaccine formulation challenges, potentially improving future product costs.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Orexo
Swedish pharmaceutical company
Nothing else this week.